ExSURE PVT. LTD.

EXSURE is an R & D-based startup and we are developing the next generation of exosome-based cancer therapeutics. We are developing a unique exosome-based chemotherapeutic drug-delivery platform that will facilitate precise and guided delivery of anti-cancer drugs (existing on the market) into tumor cells and relapse-causing cells (cancer stem cells) without abruptly harming the healthy cells. Our platform will reduce chemotoxicity and chances of cancer relapse in cancer patients. Currently, we are working with a breast cancer model. We have validated the efficiency and efficacy of our platform in vitro (in different breast cancer cell lines and derived cancer stem cells) and ex-vivo (primary cells & stem cells derived from chemo-naive clinical samples of breast tumor biopsies). We are yet to validate our platform in vivo (SCID mice). We have filed the patent for the formulation we are using to develop these bioengineered drug-loaded targeted exosomes and the methodology behind it (Final patent to be filed this month). We are providing outsourcing services including any type of cell-culture-based assays, exosome-based experimentations, and cancer stem cell-based assays.

https://exsure.in/

2-10 employees

Growth Trajectory

Exsure has significant growth potential through the development of their next-generation nano drug delivery platform and expansion of their product line to include more exosome-related tools and services. Their expansion indicators include the launch of LEUCOSURE and DENDROSURE, participation in international events, and investment from Unicorn India, indicating a strong growth trajectory in the biotech and pharmaceutical sectors.

Technical Challenges

Targeted drug delivery

Improving drug delivery efficiency

Complexity of exosome biogenesis and isolation

Complexity of glycan biochemistry in exosome biology

Dysregulation of exosome-mediated communication in diseases like cancer, neurodegenerative disorders, and inflammatory conditions.

Characterization and standardization of extracellular vesicles (EVs).

There is no sequence relationship between glycans and their conjugates other than initial attachment sites

The amount of different glycoconjugates to exosome surfaces from various sources is also uncertain

Tech Stack

Exosome isolationLymphocyte separationExosomesGlycansGlycoengineeringNanoparticlesCentrifugationColorimetric assayMass spectrometryNuclear magnetic resonanceInfrared spectroscopy

Team Size

CEO

CSO

Core Research Team

Scientific Advisory Team

Clinical Advisory Team

Business Advisory

Clinical Trial Advisor

Key Risks

Market competition from other biotech and pharmaceutical companies in the drug delivery and cancer therapy space.

Technical hurdles in developing and scaling up exosome-based therapies, including efficient drug loading and targeted delivery.

Regulatory challenges and compliance requirements for new drug therapies and clinical trials.

Complexity of glycan biochemistry in exosome biology leading to a slower pace of research.

The structures of glycans are complicated and profiling/characterising global glycosylations of a certain target type of exosome, cell or even tissue, is a huge challenge

Opportunities

Leverage the patented exosome-based platform to establish a strong market position in India and expand globally.

Capitalize on the growing market for targeted drug delivery and personalized medicine by further developing exosome-based therapeutics.

Collaborate with research institutions and pharmaceutical companies to accelerate the development and commercialization of exosome-based technologies.

Expand product line to include more exosome-related tools and services, such as diagnostic assays and regenerative medicine applications.

Innovate in Glycoengineering of exosomes has potential to activate the immune system against tumours, manipulate cargo recruitment, and provide targeted drug delivery.

Live Data Stream

Access Our Live VC Funding Database

30,000+ funded startups

tracked in the last 3 months

B2B verified emails

of key decision makers

Growth metrics

Real-time company performance data

Live updates

of new VC funding rounds

Advanced filters

for sophisticated queries

API access

with multiple export formats

Access Database

Updated every 5 minutes